New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
09:14 EDTWGO, BAX, ADXS, GME, C, YONG, LULUOn The Fly: Pre-market Movers
HIGHER: Baxter (BAX), up 9% after announcing plans to split into two separate companies... Winnebago (WGO), up 7% after quarterly results top expectations... lululemon (LULU), up 1% after quarterly earnings beat expectations, but full-year EPS view trails consensus estimate. LOWER: Citigroup (C), down 5.6% after the Federal Reserve rejected the bank's capital plan for 2014, shares were downgraded at Keefe Bruyette and Bernstein... GameStop (GME), down 4.6% after earnings and guidance miss expectations... Advaxis (ADXS), down 27% after 4.08M share spot secondary offering priced at $3.00.
News For C;BAX;LULU;GME;WGO;YONG;ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 9, 2015
19:39 EDTCCiti weighs return to Cuba, Reuters says
Subscribe for More Information
17:08 EDTCCiti head of Franchise Risk and Strategy, Brian Leach, to retire on April 30
Brian Leach, Citiís Head of Franchise Risk and Strategy, has submitted a notice of retirement to Citi. The effective date of the retirement is April 30.
07:35 EDTCFitch Ratings to hold a webcast
Subscribe for More Information
06:57 EDTCCitibank sued by Argentina over deal with creditors, Reuters reports
Citibank Argentina has been sued by Argentina over what it says is an illegal deal with a group of creditors in conflict with the government over unpaid debt, Reuters reports. Citigroup says it is "disappointed" by Argentina's legal actions and has denied violating laws. Reference Link
April 8, 2015
16:22 EDTADXSOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTCActionable Options for Wednesday, April, 8
Subscribe for More Information
10:01 EDTLULUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:27 EDTLULUlululemon rises moderately after upgrade, levels to watch
Subscribe for More Information
09:20 EDTLULUOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTLULUlululemon CFO, products leave favorable impression, says BB&T
Subscribe for More Information
07:44 EDTLULUlululemon upgraded at Sterne Agee
Subscribe for More Information
07:33 EDTADXSAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
06:29 EDTLULUlululemon upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
April 7, 2015
16:00 EDTCOptions Update; April 7, 2015
Subscribe for More Information
14:27 EDTLULUlululemon CFO impressive in meeting, says KeyBanc
KeyBanc said it was impressed by new lululemon CFO Stuart Haselden in a recent meeting and the firm believes his operational and financial experience should help the company keep improving its operations. The firm repeated that it views lululemon as one of the best product turnaround opportunities within its coverage and it maintains an Overweight rating on the stock.
11:02 EDTCAmerican Express slips after analyst, columnist highlight challenges
Subscribe for More Information
07:16 EDTCRising competition may make AmEx targets hard to achieve, WSJ says
Though American Express recently reaffirmed its long-term targets for growing revenue 8% per year or better and earnings per share by 12%-15% per year while increasing operating expenses by less than 3% per year, there are good reasons to be skeptical about its ability to hit those targets, according to The Wall Street Journal's "Heard on the Street" column. Competition from peer Visa (V) as well as big banks such as Citi (C) and Bank of America (BAC) may put pressure on AmExís margins and it is not safe to assume that the company will always fare as well on the Fed's stress tests as it just did, the report stated. Reference Link
April 6, 2015
19:33 EDTCRegulators enter headquarters of Citibank Argentina, Reuters says
Subscribe for More Information
18:18 EDTWGOWinnebago announces 2015 Apollo rental program
Subscribe for More Information
07:34 EDTADXSAdvaxis, RTOG Foundation collaborate on Phase 2/3 trial of ADXS-HPV
Advaxis announced that it is entering into a clinical trial collaboration agreement with the Radiation Therapy Oncology Group, or RTOG, Foundation to evaluate the safety and efficacy of Advaxis's lead cancer immunotherapy, ADXS-HPV, in a pivotal Phase 2/3 anal cancer trial, which will be run by NRG Oncology. ADXS-HPV is an investigational Lm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene. Under the proposed collaboration, RTOG Foundation, through its partnership with NRG Oncology, will conduct an adequate and well-controlled Phase 2/3 clinical trial of concurrent chemotherapy of mitomycin C/5FU and radiation therapy, or CCRT, compared to CCRT combined with ADXS-HPV in the adjuvant treatment of high-risk locally advanced anal cancer.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use